EGFR-Mutated NSCLC: Osimertinib & Chemotherapy – Expert Interview

For patients diagnosed with advanced non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) mutations, the treatment landscape is rapidly evolving. Recent research indicates that combining the targeted therapy osimertinib with chemotherapy offers a significant advantage over osimertinib alone, extending both progression-free and overall survival.

Historically, smoking cessation has been identified as the most impactful intervention in reducing lung cancer mortality rates. However, as Consultant Medical Oncologist Dr. Mary O’Brien of the Royal Marsden Hospital in London, UK, notes, the next major leap in improving outcomes may lie in earlier detection through screening programs.

Osimertinib Plus Chemotherapy: A New Standard of Care

The FLAURA2 trial, presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer, demonstrated a compelling benefit with the combination of osimertinib and platinum-based chemotherapy. Patients receiving this combination achieved a median overall survival of September 2025 47.5 months, nearly a 10-month improvement compared to those treated with osimertinib monotherapy (37.6 months). This represents the longest reported median overall survival in a phase III study involving patients with EGFR-mutated advanced NSCLC.

This survival benefit was observed consistently across all patient subgroups, including those with brain metastases and no new safety concerns emerged with extended follow-up. The hazard ratio for overall survival was 0.77 (P = .02), indicating a statistically significant reduction in the risk of death for those receiving the combination therapy.

Earlier findings from the COMPEL trial further support the use of osimertinib as a foundational treatment for EGFR-mutated advanced NSCLC across multiple lines of therapy. In patients experiencing non-central nervous system progression while on first-line osimertinib, adding chemotherapy was associated with improved progression-free survival (PFS) and overall survival (OS) compared to placebo plus chemotherapy. The median PFS in all patients was 8.4 months with osimertinib plus chemotherapy versus 4.4 months with placebo plus chemotherapy (hazard ratio 0.43).

Understanding EGFR-Mutated NSCLC

EGFR is a protein crucial for cell growth and division. Mutations in the EGFR gene are common drivers of NSCLC in a subset of patients. These mutations make the cancer cells more susceptible to targeted therapies like osimertinib, a tyrosine kinase inhibitor that blocks the activity of the mutated EGFR protein.

While osimertinib has become a mainstay of treatment, resistance inevitably develops over time. The FLAURA2 trial suggests that combining osimertinib with chemotherapy may delay the onset of this resistance, as well as prevent or delay intracranial progression of the disease.

CNS Involvement and Treatment Strategies

The presence of brain metastases significantly impacts the prognosis for patients with NSCLC. Research presented at the American Society of Clinical Oncology (ASCO) demonstrated that osimertinib plus platinum-pemetrexed chemotherapy showed improved central nervous system (CNS) efficacy compared to osimertinib alone, delaying CNS progression regardless of whether brain metastases were present at baseline.

This is particularly important, as brain metastases are a common site of progression in EGFR-mutated NSCLC. The ability to effectively control CNS disease is a critical goal of treatment.

Beyond First-Line Therapy

The therapeutic landscape for EGFR-mutated NSCLC extends beyond initial treatment. Novel agents, including antibody-drug conjugates, bispecific antibodies, and T-cell engagers, are emerging as promising options for patients who have been pretreated. Optimizing the treatment sequence – carefully considering which therapies to use and when – is crucial for maximizing survival and maintaining quality of life.

Dr. O’Brien’s emphasis on the impact of smoking cessation underscores the importance of preventative measures. While advancements in treatment are continually being made, preventing the disease in the first place remains paramount. The potential for widespread lung cancer screening to detect the disease at earlier, more treatable stages is an area of ongoing research and discussion.

The 10th Royal Marsden Lung Cancer Symposium is scheduled for November 17, 2027, offering a platform for continued discussion and advancement in the field of lung cancer treatment.

As Dr. Planchard stated, “This compelling overall survival result confirms osimertinib plus chemotherapy as the new first-line standard of care in EGFR-mutated, advanced, non–small cell lung cancer.”